I agree with others that a lot of uncertainty has been...

I agree with others that a lot of uncertainty has been eliminated with the latest announcement.

CZM will make payments for additional engineering works as required.
That means an end to scope creep: from here on in Optiscan gets paid for requested enhancements on an hourly basis.

These new arrangements are expected to generate cash flows to Optiscan for both the supply of services and instruments in excess of $2.2 million by the end of calendar 2016.
That is a bit disappointing as it implies it might take till end 2016 to get fully on stream with the Zeiss product. But I can live with that. That's the reality that we've been slowly seeing.

I really like the look of CellLIVE, I like the look of MRS as a sales partner. I do think there will be sales there. And there is nearly 12 months worth of money in the bank with the last raising so we are sitting pretty.

Perhaps there's a little overhang from the shortfall of the raising - perhaps there are a lot of sellers at 5c.
if we clear that it we will be on the up for sure.
good luck all.